Article
A human <i>ex vivo</i> dengue virus neutralization assay identifies priority antibodies and epitopes for vaccines and therapeutics
2019-01-10
Abstract excerpt
<h4>Background</h4> Dengue is the most prevalent arboviral disease, for which neither effective vaccines nor antivirals are available. Clinical trials with Dengvaxia, the first licensed dengue vaccine, show the conventional in vitro plaque reduction neutralization test (PRNT) failed to discriminate between neutralizing and non-neutralizing antibodies. A number of human monoclonal antibodies (mAbs) were characteri...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b5bcc45d-3cdc-5fa8-9114-dfabeebae3d0
- DOI
- 10.1101/516195